Latest Conference Articles

J&J and Biogen Discuss Their Biosimilar Strategies at J.P. Morgan Healthcare Conference

Samantha DiGrande

January 8 2019

Presenters during the 37th annual J.P. Morgan Healthcare Conference, held January 7-10 in San Francisco, California provided an overview about what potential investors can expect to see from their companies’ pharmaceutical pipelines over the next fiscal year.

At the J.P. Morgan Healthcare Conference, Coherus Outlines "Branded Approach" to Biosimilars

Kelly Davio

January 8 2019

During the second day of the 37th Annual J.P. Morgan Healthcare Conference, held January 7-10 in San Francisco, California, Dennis M. Lanfear, president and CEO of Coherus BioSciences, presented an overview of what he called his company’s “branded approach” to selling its newly launched biosimilar pegfilgrastim, Udenyca.

Pfizer and Teva Provide a Look at Their Biosimilar Ambitions on Day 1 of the J.P. Morgan Healthcare Conference

Kelly Davio

January 7 2019

During the first day of the 37th Annual J.P. Morgan Healthcare Conference, held January 7-10 in San Francisco, California, 2 major biosimilar developers gave a look at their strategies for 2019 and beyond.

FN Prophylaxis With Biosimilar Filgrastim Generates Substantial Savings Versus Pegfilgrastim On-Body Injector

Samantha DiGrande

December 5 2018

There are several options for the prophylaxis of febrile neutropenia (FN), including pegfilgrastim delivered in an on-body injector (OBI), a single injection of pegfilgrastim, and daily injections with reference filgrastim or Sandoz’ biosimilar filgrastim.

Biosimilar Beats Subcutaneous Rituximab on Cost Savings in NHL

Kelly Davio

December 5 2018

The launch of biosimilar rituximab is an eagerly awaited event among US healthcare stakeholders who are cognizant of the high cost of intravenously (IV) administered rituximab in treating non-Hodgkin lymphoma (NHL). At the same time, another innovation in rituximab delivery—a subcutaneously administered rituximab formulation—has the potential to save both cost and time.

CT-P10 Is Similar to Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma

Samantha DiGrande

December 4 2018

The study’s authors concluded that, at the median follow-up of 23 months, the data demonstrated comparable progression-free survival, sustained response, and overall survival between both the biosimilar and the reference product.

Tbo-Filgrastim Delivers VHA Cost Savings, but Could a Change of Strategy Do More?

Kelly Davio

December 4 2018

For health systems like the Veterans Health Administration (VHA), where controlling costs while providing high-quality care is of heightened concern, achieving the best value for money in the prophylaxis of neutropenia can help to control the cost of cancer care.

More Data Underscore the Safety and Efficacy of CT-P10 in Hematological Conditions

Kelly Davio

December 4 2018

Celltrion’s CT-P10, a biosimilar rituximab that was FDA approved under the brand name Truxima in November 2018, is already in wide use for a host of indications in many regulatory territories. During this week’s 60th Annual Meeting and Exposition of the American Society of Hematology in San Diego, California, multiple research teams are reporting data that underscore the safety and efficacy of CT-P10 in hematological conditions.

Biosimilar Filgrastim Performs in Stem Cell Mobilization

Samantha DiGrande

December 3 2018

In 2016, the Saskatchewan Cancer Agency switched from the brand-name filgrastim, Neupogen, to a biosimilar, Apotex’s Grastofil, for stem cell mobilization prior to autologous stem cell transplants. In a study presented at the American Society of Hematology’s Annual Meeting, researchers sought to determine the safety and efficacy of using a biosimilar for this setting.

Using Biosimilar Filgrastim Does Not Impact Plerixafor Use in Transplantation Candidates

Kelly Davio

December 2 2018

Patients who are candidates for hematopoietic stem cell transplantation (AHSCT) require adequate collection of stem cells, and granulocyte colony-stimulating factor agents (G-CSFs) are typically used for stem cell mobilization while plerixafor is used to increase the yield of mobilized stem cells. While the biosimilar filgrastim agent Zarxio has become a more widely used, cost-saving G-CSF option in this context, little research has been conducted on whether the use of the biosimilar rather than its reference, Neupogen, has an impact on plerixafor use in patients undergoing AHSCT.